Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF - April 13.03.2026 FAPR.LN IE000WX2HZQ7 150,002.00 USD 3,672,316.70 24.482  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Bloomberg Nuclear Power UCITS ETF 13.03.2026 RCTR.LN IE000J5PESP7 100,002.00 USD 1,960,614.85 19.606  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest US Equity Max Buffer UCITS ETF - December 13.03.2026 MDEC.LN IE0007FIJUO5 50,002.00 USD 1,366,974.04 27.338  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Europe Growth Strength UCITS ETF 13.03.2026 FTEG.LN IE0009F7UB30 125,002.00 EUR 2,549,101.39 20.392  ...

NEWPORT NEWS, Va.--(BUSINESS WIRE)--  On March 16, 2026, Ferguson Enterprises Inc. (the "Company") filed a Definitive Proxy Statement, Definitive Additional Proxy Soliciting Material and Transition Report to Security Holders with the U.S. Securities and Exchange Commission ("SEC"). The filings are available on the SEC's website at sec.gov and on the SEC Filings page of the Company’s website at corporate.ferguson.com. March 16, 2026 – Definitive Proxy Statement (DEF 14A) March 16, 2026 – Definit...

NEWPORT NEWS, Va.--(BUSINESS WIRE)--On March 16, 2026, Ferguson Enterprises Inc. (the "Company") filed a Definitive Proxy Statement, Definitive Additional Proxy Soliciting Material and Transition Report to Security Holders with the U.S. Securities and Exchange Commission ("SEC"). The filings are available on the SEC's website at sec.gov and on the SEC Filings page of the Company’s website at corporate.ferguson.com. March 16, 2026 – Definitive Proxy Statement (DEF 14A) March 16, 2026 – Definitiv...

LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) today announced that it has entered into a definitive arrangement agreement (the “Arrangement Agreement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its affiliate (the “Purchaser”) pursuant to which the Purchaser will acquire all of the issued and outstanding common shares of the Company (the “Shares”) in exchange for all-cash consideration (the “Arrangement”). The target pu...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Emerging Markets AlphaDEX UCITS ETF 13.03.2026 FEM IE00B8X9NX34 325,002.00 USD 14,907,756.89 45.870  ...

DALLAS--(BUSINESS WIRE)--Flowserve Corporation (NYSE:FLS), a leading provider of flow control products and services for the global infrastructure markets, announced today that its Board of Directors has elected Brian Savoy as a member of the Board of Directors, and appointed him to the Audit Committee and Technology, Innovation and Risk Committee, effective March 16, 2026. “We are incredibly excited to have Brian join Flowserve’s Board,” said Scott Rowe, Flowserve President and Chief Executive...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN) today reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting progress for the botensilimab (BOT) plus balstilimab (BAL) immunotherapy program across patient access, clinical execution, and commercial readiness. BOT+BAL is a next-generation CTLA-4/PD-1 immunotherapy combination which activates both innate and adaptive immunity and has demonstrated immunotherapy benefit in tumors historica...